EU Regulators Ramp Up Safety Monitoring Efforts For Biologicals
This article was originally published in SRA
It is well known that biological medicinal products are different from chemically synthesized medicines and that these differences are recognized in terms of the data required to support their evaluation. Regulatory authorities are now ramping up efforts to produce dedicated programs and guidance to support the pharmacovigilance of biologicals, reports Vibha Sharma.
You may also be interested in...
A new draft guideline from the European Medicines Agency on pharmacovigilance requirements relating to medicines taken during pregnancy and breastfeeding has been delayed and will now be issued for stakeholder consultation by the end of 2017.
EU pharmaceutical companies believe that batch traceability and product identification requirements in the European Medicines Agency's recently-finalized guideline on pharmacovigilance of biological medicines does not take into account the realities and practicalities of marketing such products.
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.